Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.

Antiviral therapy - 1 Jan 2018

Hagiwara Satoru, Nishida Naoshi, Watanabe Tomohiro, Ida Hiroshi, Sakurai Toshiharu, Ueshima Kazuomi, Takita Masahiro, Komeda Yoriaki, Nishijima Norihiro, Osaki Yukio, Kudo Masatoshi

Abstract excerpt

BACKGROUND: Although the efficacy of combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported in patients with chronic hepatitis B (CHB), the long-term effect of the combination based on the observation of clinical course remains to be clarified. We previously reported the efficacy of combination therapy with entecavir (ETV) and PEG-IFN. Here, we investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Guanine
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B Surface Antigens

Share to Interferon-alpha

Share to Lamivudine

Share to Polyethylene Glycols

Share to Recurrence

Share to Sustained Virologic Response

Source

Identifiers

PMID: 29438098
DOI: 10.3851/IMP3225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.PMID 29438098Read ↗

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.Semantic proximity Read ↗

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.Semantic proximity Read ↗

Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.Semantic proximity Read ↗

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.Semantic proximity Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.Semantic proximity Read ↗

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.Semantic proximity Read ↗

Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.Semantic proximity Read ↗

High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.Semantic proximity Read ↗

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.Semantic proximity Read ↗

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.